These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

586 related items for PubMed ID: 15284295

  • 1. Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein.
    Zhang G, Cai X, López-Guisa JM, Collins SJ, Eddy AA.
    J Am Soc Nephrol; 2004 Aug; 15(8):2090-102. PubMed ID: 15284295
    [Abstract] [Full Text] [Related]

  • 2. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A, Xue M, Jackson C, Smith RC.
    Int J Biochem Cell Biol; 2009 Aug; 41(8-9):1731-8. PubMed ID: 19433314
    [Abstract] [Full Text] [Related]

  • 3. Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice.
    Gu JM, Johns A, Morser J, Dole WP, Greaves DR, Deng GG.
    J Cell Physiol; 2005 Jul; 204(1):73-82. PubMed ID: 15573379
    [Abstract] [Full Text] [Related]

  • 4. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B, Nakamura M, Zhou G, Ishii A, Nakamura A, Bai Y, Mori I, Kakudo K.
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [Abstract] [Full Text] [Related]

  • 5. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A, Brun P, Sartori MT, Cortivo R, Dedominicis C, Saggiorato G, Abatangelo G, Secchi AG.
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [Abstract] [Full Text] [Related]

  • 6. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
    Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Choi I, Lee JH.
    Cancer Res; 2003 Aug 01; 63(15):4648-55. PubMed ID: 12907645
    [Abstract] [Full Text] [Related]

  • 7. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
    Nordengren J, Pilka R, Noskova V, Ehinger A, Domanski H, Andersson C, Høyer-Hansen G, Hansson SR, Casslén B.
    Mol Hum Reprod; 2004 Sep 01; 10(9):655-63. PubMed ID: 15243126
    [Abstract] [Full Text] [Related]

  • 8. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M, Masanobu M, Takehiko K, Shoko T, Akira F, Katsushige A, Takashi H, Yoshiyuki O, Shigeru K.
    J Lab Clin Med; 2004 Aug 01; 144(2):69-77. PubMed ID: 15322501
    [Abstract] [Full Text] [Related]

  • 9. Involvement of the [uPAR:uPA:PAI-1:LRP] complex in human myogenic cell motility.
    Chazaud B, Bonavaud S, Plonquet A, Pouchelet M, Gherardi RK, Barlovatz-Meimon G.
    Exp Cell Res; 2000 Aug 01; 258(2):237-44. PubMed ID: 10896774
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H, Manabe T.
    BMC Cell Biol; 2006 Feb 20; 7():8. PubMed ID: 16504015
    [Abstract] [Full Text] [Related]

  • 11. Endogenous urokinase lacks antifibrotic activity during progressive renal injury.
    Yamaguchi I, Lopez-Guisa JM, Cai X, Collins SJ, Okamura DM, Eddy AA.
    Am J Physiol Renal Physiol; 2007 Jul 20; 293(1):F12-9. PubMed ID: 17356128
    [Abstract] [Full Text] [Related]

  • 12. Expression and function of the urokinase type plasminogen activator during mouse hemochorial placental development.
    Teesalu T, Blasi F, Talarico D.
    Dev Dyn; 1998 Sep 20; 213(1):27-38. PubMed ID: 9733098
    [Abstract] [Full Text] [Related]

  • 13. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 20; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 14. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view.
    Binder BR, Mihaly J, Prager GW.
    Thromb Haemost; 2007 Mar 20; 97(3):336-42. PubMed ID: 17334498
    [Abstract] [Full Text] [Related]

  • 15. Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes.
    Del Rosso A, Cinelli M, Guiducci S, Pignone A, Fibbi G, Margheri F, Gabrielli A, Giacomelli R, Coppini A, Del Rosso M, Matucci Cerinic M.
    Rheumatology (Oxford); 2005 Oct 20; 44(10):1255-62. PubMed ID: 15998634
    [Abstract] [Full Text] [Related]

  • 16. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C, Yu J, Huang S.
    Mol Carcinog; 2007 Mar 20; 46(3):165-75. PubMed ID: 17186542
    [Abstract] [Full Text] [Related]

  • 17. A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts.
    Mazzieri R, Furlan F, D'Alessio S, Zonari E, Talotta F, Verde P, Blasi F.
    Oncogene; 2007 Feb 01; 26(5):725-32. PubMed ID: 16878153
    [Abstract] [Full Text] [Related]

  • 18. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V, Bürgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F, Kellermann J, Degitz K, Wilhelm OG, Schmitt M, Kessler H.
    Biol Chem; 2001 Aug 01; 382(8):1197-205. PubMed ID: 11592401
    [Abstract] [Full Text] [Related]

  • 19. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V, Schroeder J, Denkert C, Kristiansen G, Schnorr D, Loening SA, Jung K, Staack A.
    Oncol Rep; 2004 Oct 01; 12(4):909-13. PubMed ID: 15375521
    [Abstract] [Full Text] [Related]

  • 20. Physical association of uPAR with the alphaV integrin on the surface of human NK cells.
    Gellert GC, Goldfarb RH, Kitson RP.
    Biochem Biophys Res Commun; 2004 Mar 19; 315(4):1025-32. PubMed ID: 14985115
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.